Insmed Incorporated  

(Public, NASDAQ:INSM)   Watch this stock  
Find more results for INSM
+1.46 (5.98%)
Feb 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 21.90 - 25.91
52 week 11.49 - 33.94
Open 24.49
Vol / Avg. 2.51M/966,497.00
Mkt cap 2.10B
P/E     -
Div/yield     -
EPS -3.12
Shares 76.59M
Beta 1.09
Inst. own 101%
May 1, 2018
Q1 2018 Insmed Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 14, 2018
Insmed Inc at Cowen Health care Conference - 10:40AM EDT - Add to calendar
Feb 23, 2018
Q4 2017 Insmed Inc Earnings Release
Feb 23, 2018
Q4 2017 Insmed Inc Earnings Call - Webcast
Feb 14, 2018
Insmed Inc at Leerink Partners Global Healthcare Conference
Jan 3, 2018
Insmed Inc Announces Additional Data from ALIS Phase 3 Clinical Program Conference Call - Webcast
Dec 5, 2017
Insmed Inc at Nasdaq Investor Program - Webcast
Nov 29, 2017
Insmed Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -53.94% -59.30%
Return on average equity -71.80% -75.62%
Employees 161 -
CDP Score - -


10 Finderne Ave Bldg 10
BRIDGEWATER, NJ 08807-3365
United States - Map
+1-908-9779900 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.

Officers and directors

William H. Lewis President, Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Paolo Tombesi Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
S. Nicole Schaeffer Senior Vice President- Human Resource and Corporate Services
Age: 48
Bio & Compensation  - Reuters
Walter Perkins Ph.D. Chief Technology Officer
Bio & Compensation  - Reuters
Eugene Jeffrey Sullivan M.D. Chief Product Strategy Officer and Chief Scientific Officer
Age: 52
Bio & Compensation  - Reuters
Christine A. Pellizzari General Counsel, Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Roger Adsett Chief Commercial Officer
Age: 48
Bio & Compensation  - Reuters
Paul Streck Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Donald J. Hayden Jr. Non-Executive Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Alfred F. Altomari Independent Director
Age: 58
Bio & Compensation  - Reuters